Bosmolisib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Bosmolisib
- Molecular weight
- 478.34
- Structure (SMILES)
- C[C@H](Nc1ncnc2[nH]ccc(=O)c12)c1c(Cl)c2cccc(Cl)c2c(=O)n1-c1ccccc1
- 4 1s 1 4 8 dichloro 1 oxo 2 phenyl 3 isoquinolyl ethyl amino 8h pyrido 2 3 d pyrimidin 5 one
- 4-[[(1S)-1-(4, 8-Dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H- pyrido[2,3-d] pyrimidin-5-one]
- bosmolisib
- Bosmolisib
- bosmolisib [INN]
- bosmolisib inn
- br 101801
- BR-101801
- br101801
- BR101801
- BR101801 (Phase Ia)
- BR101801 (Phase Ib)
- CAS registry numbers
- 2055765-77-8
- ChEMBL ID
- CHEMBL6068044
- InChIKey
- HIXUFHUKIOTXLJ-ZDUSSCGKSA-N
- PubChem compound IDs
- 134427646
- FDA ingredient codes (UNII)
- FJ5CTS1VNJ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- bosmolisib
- Type
- Synthetic organic
- Drug name stem
- -lisib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
- Gene symbol
- PIK3CD
- Protein identifier
- O00329
- Median affinity
- 8.7
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
- Gene symbol
- PIK3CG
- Protein identifier
- P48736
- Median affinity
- 7.82
- Affinity units
- pIC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0000430
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004948
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0015759
- Highest recorded phase
- 1
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 92.67
- Calculated partition coefficient (ALogP)
- 5.1
- Calculated partition coefficient (XLogP)
- 5.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 33
- Molecular formula
- C24H17Cl2N5O2
- Monoisotopic mass
- 477.0759302
- Natural product
- No
Related records
Trials (15)
- A Phase I Study of CFT8919 in Patients With Advanced NSCLC
- A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
- A Study of HS-20089 in Patients With Advanced Solid Tumors
- A Study of HS-20110 in Participants With Advanced Solid Tumors
- A Study of HS-20124 in Patients with Advanced Solid Tumors
- ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma
- IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
- Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
- Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
- This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
- Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
In development for (2)
- Mature T-cell and NK-cell non-Hodgkin lymphoma Phase 2
- Neoplasm Phase 2